Urinary N-Terminal Pro-Brain Natriuretic Peptide Predicts Acute Kidney Injury and Severe Disease in COVID-19

Bibliographic Details
Title: Urinary N-Terminal Pro-Brain Natriuretic Peptide Predicts Acute Kidney Injury and Severe Disease in COVID-19
Authors: Manuel Julian Vogel, Simon B Leininger, Stephan T Staudner, Ute Hubauer, Stefan Wallner, Julian Mustroph, Frank Hanses, Markus Zimmermann, Petra Lehn, Ralph Burkhardt, Lars S Maier, Julian Hupf, Carsten G Jungbauer
Source: Kidney & Blood Pressure Research, Vol 48, Iss 1, Pp 424-435 (2023)
Publisher Information: Karger Publishers, 2023.
Publication Year: 2023
Collection: LCC:Dermatology
LCC:Diseases of the circulatory (Cardiovascular) system
LCC:Diseases of the genitourinary system. Urology
Subject Terms: covid-19, n-terminal pro-brain natriuretic peptide, acute kidney injury, urinary biomarkers, Dermatology, RL1-803, Diseases of the circulatory (Cardiovascular) system, RC666-701, Diseases of the genitourinary system. Urology, RC870-923
More Details: Introduction: The ongoing COVID-19 pandemic is placing an extraordinary burden on our health care system with its limited resources. Accurate triage of patients is necessary to ensure medical care for those most severely affected. In this regard, biomarkers could contribute to risk evaluation. The aim of this prospective observational clinical study was to assess the relationship between urinary N-terminal pro-brain natriuretic peptide (NT-proBNP) and acute kidney injury (AKI) as well as severe disease in patients with COVID-19. Methods: 125 patients treated with an acute respiratory infection in the emergency department of the University Hospital Regensburg were analyzed. These patients were divided into a COVID-19 cohort (n = 91) and a cohort with infections not caused by severe acute respiratory syndrome-coronavirus-2 (n = 34). NT-proBNP was determined from serum and fresh urine samples collected in the emergency department. Clinical endpoints were the development of AKI and a composite one consisting of AKI, intensive care unit admission, and in-hospital death. Results: 11 (12.1%) COVID-19 patients developed AKI during hospitalization, whereas 15 (16.5%) reached the composite endpoint. Urinary NT-proBNP was significantly elevated in COVID-19 patients who suffered AKI or reached the composite endpoint (each p < 0.005). In a multivariate regression analysis adjusted for age, chronic kidney disease, chronic heart failure, and arterial hypertension, urinary NT-proBNP was identified as independent predictor of AKI (p = 0.017, OR = 3.91 [CI: 1.28–11.97] per standard deviation [SD]), as well as of the composite endpoint (p = 0.026, OR 2.66 [CI: 1.13–6.28] per SD). Conclusion: Urinary NT-proBNP might help identify patients at risk for AKI and severe disease progression in COVID-19.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1420-4096
1423-0143
Relation: https://beta.karger.com/Article/FullText/529690; https://doaj.org/toc/1420-4096; https://doaj.org/toc/1423-0143
DOI: 10.1159/000529690
Access URL: https://doaj.org/article/4429c5764d084d199e5b3974188be022
Accession Number: edsdoj.4429c5764d084d199e5b3974188be022
Database: Directory of Open Access Journals
More Details
ISSN:14204096
14230143
DOI:10.1159/000529690
Published in:Kidney & Blood Pressure Research
Language:English